The global pharmaceutical packaging equipment market is anticipated to reach a valuation of US$ 5.6 billion in 2023, driven by growing biopharmaceutical industry. The trend is expected to create new opportunities for the market,
Algorae Pharmaceuticals is finding ways to revamp its process of drug development from cost saving and speed to timeline of drug research and delivery by
“Malaysia is expected to reach US$5.9 billion by 2030, so this is where we can work together with the Islamic Development Bank (IsDB) to get our halal pharmaceutical products enter this new market among the Organisation of Islamic Cooperation (OIC) and Saudi Arabia,” he told Bernama.
Eli Lilly may be on the verge of another breakthrough, thanks to its hit GLP-1 medications. One of the hottest areas in the pharmaceutical space right now is weight loss. Glucagon-like peptide-1 (GLP-1) medications such as Ozempic, Wegovy, Rybelsus …
Few things are as frustrating as medical care in the United States. Too often when patients complain about minor ailments to their family doctor, they are passed off to specialists
Tower Cold Chain introduces a pyramid, the Port of Savannah gets a new neighbor, and consumer spending negatively impacts Nestle. The post Running on Ice: Pyramids and the pharmaceutical supply chain appeared first on FreightWaves.
Eli Lilly and Company has acquired a state-of-the-art injectable medicine manufacturing facility from Nexus Pharmaceuticals LLC. The acquisition of this FDA-approved facility in Pleasant Prairie further expands Lilly’s global parenteral injectable product manufacturing network and supports increased demand for the company’s medicines.
Global Pharmaceutical Dissolution Testing Services Industry value of US$ 693.12 Million in 2023, by registering a CAGR of 8.3% By 2033
BioMarin Pharmaceutical Inc. beats earnings expectations. Reported EPS is $0.71, expectations were $0.6. BioMarin Pharmaceutical Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).
Investments in drug research and development are paying dividends while the cost to do so stays flat, a trend that appears to be benefitting local firms. Large pharmaceutical companies’ returns on research and development investments rebounded in 2023,